Gene study aims to predict fertility risk after chemo
NCT ID NCT07270679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether certain genetic markers can predict which young women (ages 18-38) with breast cancer or Hodgkin lymphoma are more likely to experience early menopause and infertility after chemotherapy. Researchers will analyze stored ovarian tissue from 50 patients who had fertility preservation before treatment. The goal is to compare DNA repair genes between those who developed ovarian failure and those who did not, to better personalize fertility counseling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients are at higher risk of ovarian damage from chemotherapy, allowing for personalized fertility preservation counseling.
What could go wrong
This is a small, observational study (50 participants) that looks at genetic markers, not a treatment. It may not lead to immediate clinical changes, and results may not apply to all cancer types or treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITINGBologna, Bologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••